The efficacy of bevacizumab in addition to platinum-based chemotherapy for first-line treatment of patients with advanced nonsquamous non-small-cell lung cancer (NSCLC): Final results of AVALANCHE, an observational cohort study.

Observational Cohort ◽

The efficacy and safety of bevacizumab in addition to platinum‑based chemotherapy for the first‑line treatment of patients with advanced nonsquamous non‑small‑cell lung cancer: Final results of AVALANCHE, an observational cohort study

Oncology Letters ◽

10.3892/ol.2018.9766 ◽

2018 ◽

Cited By ~ 1

Author(s):

Edina Tolnay ◽

�ron Ghimessy ◽

Erzs�bet Juh�sz ◽

Zsuzsanna Sztancsik ◽

Gy�rgy Losonczy ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Observational Cohort Study ◽

Line Treatment ◽

Efficacy And Safety ◽

Small Cell Lung ◽

First Line ◽

Observational Cohort ◽

A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903

ESMO Open ◽

10.1016/j.esmoop.2021.100115 ◽

2021 ◽

Vol 6 (3) ◽

pp. 100115

Author(s):

K. Ito ◽

M. Morise ◽

K. Wakuda ◽

O. Hataji ◽

T. Shimokawaji ◽

...

Keyword(s):

Lung Cancer ◽

Cohort Study ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Multicenter Cohort Study ◽

Multicenter Cohort ◽

Egfr Mutated ◽

Crizotinib vs platinum‐based chemotherapy as first‐line treatment for advanced non‐small cell lung cancer with different ROS1 fusion variants

Cancer Medicine ◽

10.1002/cam4.2984 ◽

2020 ◽

Vol 9 (10) ◽

pp. 3328-3336 ◽

Cited By ~ 3

Author(s):

Haiyan Xu ◽

Quan Zhang ◽

Li Liang ◽

Junling Li ◽

Zhefeng Liu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Durvalumab with or without tremelimumab vs platinum-based chemotherapy as first-line treatment for metastatic non-small cell lung cancer: MYSTIC

Annals of Oncology ◽

10.1093/annonc/mdy511.005 ◽

2018 ◽

Vol 29 ◽

pp. x40-x41 ◽

Cited By ~ 41

Author(s):

N.A. Rizvi ◽

B. Chul Cho ◽

N. Reinmuth ◽

K.H. Lee ◽

M.-J. Ahn ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

PCN82 Cost-Effectiveness Analysis of Erlotinib Versus Platinum Based Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer EGFR Activating Mutations

Value in Health ◽

10.1016/j.jval.2012.08.2122 ◽

2012 ◽

Vol 15 (7) ◽

pp. A424

Author(s):

P. Garrido ◽

G. López-Vivanco ◽

R. Rosell ◽

B. Espinós ◽

A. Castro-Gomez

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Activating Mutations ◽

Effectiveness Analysis ◽

First-Line Treatment with Bevacizumab and Platinum Doublet Combination in Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Cohort Study in US Oncology Community Practices

Drugs - Real World Outcomes ◽

10.1007/s40801-016-0090-5 ◽

2016 ◽

Vol 3 (3) ◽

pp. 333-343 ◽

Cited By ~ 5

Author(s):

Orsolya E. Lunacsek ◽

Arliene Ravelo ◽

Anna D. Coutinho ◽

Sebastien J. Hazard ◽

Mark R. Green ◽

...

Keyword(s):

Lung Cancer ◽

Cohort Study ◽

Retrospective Cohort Study ◽

Retrospective Cohort ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

First Line Treatment ◽

Platinum Doublet

Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants

Annals of Oncology ◽

10.1093/annonc/mdz260.075 ◽

2019 ◽

Vol 30 ◽

pp. v640

Author(s):

H. Xu ◽

Q. Zhang ◽

L. Liang ◽

J. Li ◽

Z. Liu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Evaluation of epidermal growth factor receptor (EGFR) as a prognostic factor for survival in non-small-cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy as first-line treatment

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.7024 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 7024-7024 ◽

Cited By ~ 2

Author(s):

M. Janas ◽

L. R. Bailey ◽

K. Schmidt ◽

N. Bindslev ◽

M. Wolf ◽

...

Keyword(s):

Lung Cancer ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

Nsclc Patients ◽

PCN40 Cost-Utility Analysis of Pembrolizumab Versus Platinum Based Chemotherapy As the First-LINE Treatment for Advanced and Metastatic NON-SMALL CELL LUNG Cancer (NSCLC) in UK

Value in Health Regional Issues ◽

10.1016/j.vhri.2020.07.090 ◽

2020 ◽

Vol 22 ◽

pp. S12

Author(s):

J. Verma ◽

D. Verma ◽

A. Maria

Keyword(s):

Lung Cancer ◽

Cost Utility ◽

Small Cell ◽

Cost Utility Analysis ◽

Line Treatment ◽

Utility Analysis ◽

Small Cell Lung ◽

First Line ◽

Weekly and every 2 weeks cetuximab maintenance therapy after platinum-based chemotherapy plus cetuximab as first-line treatment for non-small cell lung cancer: randomized non-comparative phase IIIb NEXT trial

Targeted Oncology ◽

10.1007/s11523-014-0336-7 ◽

2014 ◽

Vol 10 (2) ◽

pp. 255-265 ◽

Cited By ~ 7

Author(s):

David F. Heigener ◽

José Rodrigues Pereira ◽

Enriqueta Felip ◽

Juraj Mazal ◽

Lyudmila Manzyuk ◽

...

Keyword(s):

Lung Cancer ◽

Maintenance Therapy ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Phase Iiib ◽